

Nirsevimab



Nirsevimab (brand name Beyfortus™)

Nirsevimab is a monoclonal antibody that helps prevent serious illness from RSV. Nirsevimab provides passive immunity. It is not a vaccine, but is an immunization. It can also be referred to as a preventative medication.

Nirsevimab is given through one intramuscular injection. It provides protection for around 5 months.

Dosage and Packaging

Nirsevimab is packaged in pre-filled syringes of either:

- 50mg (0.5mL) with purple plunger rod (for infants weighing <5 kg)
- 100 mg (1mL) with light blue plunger rod (weighing ≥5kg)

Nirsevimab is recommended for:

- Newborns who are born during the RSV season.
- Babies who are less than 1 year old who are entering their first RSV season.
- Children up to 2 years old, who are at risk of severe RSV disease. Children receiving nirsevimab in their second RSV season should receive a single dose of 200 mg, administered through 2 separate 100 mg IM injections.

The formulation of nirsevimab will not change from year to year. Nirsevimab has a shelf life of about 18 months.

Nirsevimab purchase cost

The private-sector cost for nirsevimab is:

- \$495 per dose for 50mg and 100mg doses
- \$990 per dose for a 200mg dose

Clinical Resources

AAP Recommendations

- Red Book: **Respiratory Syncytial Virus Chapter**
- Red Book Online: **ACIP and AAP Recommendations for Nirsevimab**

CDC

- **Immunity Types**
- ACIP June 2023 Slides: **Respiratory Syncytial Virus Vaccines – Pediatric/Maternal**

Additional Resources

- Beyfortus **prescribing information**
- AAP **Nirsevimab Coding & Payment**
- American Medical Association **Category I Immunization Codes**

Nirsevimab

Nirsevimab or Palivizumab?

According to the AAP's clinical guidance, palivizumab should not be administered the same if nirsevimab has been given. If an infant started palivizumab, but did not receive all 5 doses, they should receive one dose of nirsevimab and no more palivizumab.

If palivizumab was given during a child's first RSV season and they are eligible for RSV prevention medication in the next, they child should receive nirsevimab. If nirsevimab is not available, the child should receive palivizumab.

Cost, Reimbursement and Coding

Proprietary Name	Manufacturer	Unit of Sale NDC11	CVX description	CVX Code	MVX Code	CPT Code
BEYFORTUS	Sanofi Pasteur Inc.	49281-0575-15	RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months	306	PMC	90380
BEYFORTUS	Sanofi Pasteur Inc.	49281-0574-15	RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months	307	PMC	90381
Administration Code: Do not report immunization administration codes 90461–90462 or 90471–90472 for the injection of nirsevimab, as these codes are limited to the administration of vaccine and toxoid products.						96372

- Follow state specifications for reporting the immunization when the immunoglobulin product is provided through the Vaccines for Children program. For example, report 90380 SL to indicate state-supplied product.
- Do not report immunization administration codes 90461–90462 or 90471–90472 for the injection of nirsevimab, as these codes are limited to the administration of vaccine and toxoid products.

Education and Resources for Patients and Families

- Yale Medicine: [Should Your Kids Get the New RSV Monoclonal Antibody?](#)
- AAP [Nirsevimab Coding & Payment](#)
- American Medical Association [Category I Immunization Codes](#)